Bio Protocol

In its May 2024 introduction, BIO presented a shared funding network for BioDAOs and described its separation from Molecule. Existing research communities were the starting point: Genesis would gather their token holders around a common treasury. This was a financing design, not a transfer of every community’s patents into BIO.

The first Genesis round took place in August 2024, according to the project’s later account. Participants exchanged BioDAO tokens for BIO before BIO became transferable. The treasury thus acquired exposure to the communities the network intended to support. The second-round design added ETH, widening the assets participants could contribute.

On 3 January 2025, the project announced BIO going live on Ethereum and Binance. A token acquired during a pre-transfer auction could now reach a broader trading market. That changed access and liquidity; it did not accelerate an experiment by itself.

BIO began with 3.32 billion units: 56% community, 13.6% early backers, 21.2% contributors, 4.2% advisers and 5% Molecule. Different cliffs and releases mean the community label did not make every unit liquid at launch.

The unresolved supply question concerns the route to issuance, not whether 3.32 billion is a cap. Basic Token Information calls BIO uncapped but says expansion needs a replacement contract; the reviewed Ethereum code exposes a minter role without a coded maximum. Those descriptions need reconciliation, and the reviewed sources do not establish every current role holder.

The V2 announcement, dated 30 July 2025 on the article itself, said earlier large, one-off raises had produced unrealistic opening valuations and misaligned incentives. Its response was smaller fixed-price launches and continuing market-based funding. This diagnosis belongs to the project; it is not independent proof that V2 solved the problem.

A holder can lock BIO for 1 to 104 weeks. veBIO weight rises with amount and remaining time, then decays unless renewed. BioXP is a separate platform score whose earning rules and benefits can change.

V2 project launches sell a project token, form automated-market liquidity and use BioXP to ration oversubscribed sales. Trades pay a documented 1% fee split 70% to the project and 30% to Bio Protocol. Market thresholds can release more funding, but they are not laboratory milestones.

BIO, BioDAO tokens, IP-Tokens and BioAgent tokens are different instruments. Project-specific IP documents may give information, governance or access, while the IP owner decides whether commercialization proceeds are shared.

Governance is also still moving from BIO and vBIO toward veBIO. Platform terms keep operating discretion with BIO.XYZ and early treasuries may use council multisigs. BIO accelerated selection and financing; whether the chosen science becomes defensible intellectual property or a medicine is decided later by researchers, contracts, regulators and experiments.